Trial Profile
A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Achieve Life Sciences; OncoGenex Pharmaceuticals
- 01 Aug 2017 According to Achieve Life Sciences media release, Achieve Life Sciences merged with OncoGenex Pharmaceuticals and the later changed its name to Achieve Life Sciences.
- 01 Dec 2008 New trial record.